(2S)-2-(3,4-dichlorophenyl)pent-4-enal | 173457-52-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2S)-2-(3,4-dichlorophenyl)pent-4-enal
• 英文别名: (S)-2-(3,4-dichlorophenyl)-4-pentenal
• CAS: 173457-52-8
• 化学式: C₁₁H₁₀Cl₂O
• 分子量: 229.106
• InChiKey: OSJSCVZFFGVJBC-SECBINFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (2S)-2-(3,4-dichlorophenyl)pent-4-enal 在 三氟化硼乙醚 、 二丁基二氯化锡 、 水 、 苯基锂 、 sodium sulfate 作用下， 以 二氯甲烷 为溶剂， 反应 17.25h， 生成 (3R)-3-[(1S)-1-(3,4-dichlorophenyl)but-3-enyl]-2-ethyl-2,3-dihydroisoindol-1-one
  参考文献：
  名称：

  Addition of Transiently-Generated Methyl o-Lithiobenzoate to Imines. An Isoindolone Annulation

  摘要：

  Addition of phenyllithium to a mixture of an imine, methyl o-iodobenzoate, and BF3 . etherate at -105 degrees C gives good to excellent yields of isoindolones. The transient formation of methyl o-lithiobenzoate is proposed, which is formed by a rapid lithium/iodide exchange reaction of the phenyllithium with methyl o-iodobenzoate in the presence of the imine. The transiently generated anions can then be captured by the BF3-activated imines to form the isoindolones in good to high yield. The reactions conditions are sufficiently mild, and selective, to permit functional groups such carbmethoxy and aryl bromide, which could otherwise react with the added PhLi, to be tolerated.

  DOI：

  10.1021/jo960582w
• 作为产物：
  描述：

  (S)-2-(3,4-dichlorophenyl)pent-4-enoyl chloride 在 tri-tert-butoxyaluminum hydride 作用下， 以 二乙二醇二甲醚 为溶剂， 反应 2.0h， 生成 (2S)-2-(3,4-dichlorophenyl)pent-4-enal
  参考文献：
  名称：

  Addition of Transiently-Generated Methyl o-Lithiobenzoate to Imines. An Isoindolone Annulation

  摘要：

  Addition of phenyllithium to a mixture of an imine, methyl o-iodobenzoate, and BF3 . etherate at -105 degrees C gives good to excellent yields of isoindolones. The transient formation of methyl o-lithiobenzoate is proposed, which is formed by a rapid lithium/iodide exchange reaction of the phenyllithium with methyl o-iodobenzoate in the presence of the imine. The transiently generated anions can then be captured by the BF3-activated imines to form the isoindolones in good to high yield. The reactions conditions are sufficiently mild, and selective, to permit functional groups such carbmethoxy and aryl bromide, which could otherwise react with the added PhLi, to be tolerated.

  DOI：

  10.1021/jo960582w

文献信息

• Piperidine derivatives useful as neurokinin antagonists
  申请人：Zeneca Limited

  公开号：US05635509A1

  公开（公告）日：1997-06-03

  Compounds of formula I ##STR1## wherein Q.sup.1, Q.sup.2, Q.sup.3, and Q.sup.4 have any of the meanings given in the specification, their N-oxides, and their pharmaceutically acceptable salts are nonpeptide antagonists of neurokinin A and useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.

  式I的化合物##STR1##其中Q.sup.1、Q.sup.2、Q.sup.3和Q.sup.4具有规范中给定的任何含义，它们的N-氧化物以及它们的药用盐是神经激肽A的非肽类拮抗剂，用于治疗哮喘等。还公开了制药组合物、制备式I化合物和中间体的方法。
• Neurokinin antagonists for use as medicaments
  申请人：——

  公开号：US20030158170A1

  公开（公告）日：2003-08-21

  A compound having the general formula (I) and methods of using such compounds for the treatment of diseases and pharmaceutical composition comprising such compounds.

  一种具有通式(I)的化合物，以及使用此类化合物治疗疾病的方法和包含此类化合物的制药组合物。
• New neurokinin antagonists for use as medicaments
  申请人：Albert Scott Jeffrey

  公开号：US20070021406A1

  公开（公告）日：2007-01-25

  The present application relates to internally cyclized naphthamide compounds of the formula Ia (wherein R 1a , R 1b , R 1c , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , X 1 , X 2 , Y, Z, and n are as defined herein), which are useful, for example, for antagonizing the pharmacological actions of the neurokinin 1 (NK 1 ) receptor. In particular, these compounds are useful in the treatment of diseases in which Substance P is involved such as, for example, major depressive disorder, severe anxiety disorders, stress disorders, major depressive disorder with anxiety, eating disorders, bipolar disorder, substance use disorder, schizophrenic disorders, psychotic disorders, movement disorders, cognitive disorders, depression and/or anxiety, mania or hypomania, aggressive behaviour, obesity, rheumatoid arthritis, Alzheimer's disease, cancer, oedema, allergic rhinitis, inflammation, pain, gastrointestinal-hypermotility, Huntington's disease, chronic obstructive pulmonary disorder (COPD), hypertension, migraine, bladder hypermotility, and urticaria.

  本申请涉及公式Ia的内环化萘酰胺化合物（其中R1a，R1b，R1c，R2，R3，R4，R5，R6，R7，R8，X1，X2，Y，Z和n的定义如本文所述），这些化合物可用于拮抗神经激肽1（NK1）受体的药理作用。特别地，这些化合物可用于治疗与物质P有关的疾病，例如重度抑郁障碍、严重焦虑障碍、应激障碍、伴有焦虑的重度抑郁障碍、进食障碍、躁狂障碍、物质使用障碍、精神分裂障碍、精神病性障碍、运动障碍、认知障碍、抑郁和/或焦虑、狂躁或亢进行为、肥胖症、类风湿性关节炎、阿尔茨海默病、癌症、水肿、过敏性鼻炎、炎症、疼痛、胃肠道高动力性、亨廷顿病、慢性阻塞性肺疾病（COPD）、高血压、偏头痛、膀胱高动力性和荨麻疹。
• Heterocyclic compounds
  申请人：ZENECA LIMITED

  公开号：EP0680962A2

  公开（公告）日：1995-11-08

  Compounds of formula I wherein Q1, Q2, Q3, Q4, Q5 and T have any of the meanings given in the specification, their N-oxides, their quaternary ammonium salts, and their pharmaceutically acceptable salts are nonpeptide antagonists of neurokinin A and useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.

  式 I 的化合物 其中 Q1、Q2、Q3、Q4、Q5 和 T 具有说明书中给出的任何含义，它们的 N-氧化物、季铵盐和它们的药学上可接受的盐是神经激肽 A 的非肽拮抗剂，可用于治疗哮喘等。还公开了药物组合物、制备式 I 化合物的工艺和中间体。
• NEW NEUROKININ ANTAGONISTS FOR USE AS MEDICAMENTS
  申请人：AstraZeneca AB

  公开号：EP1276729A1

  公开（公告）日：2003-01-22